DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 2013--------------------------------------------------
       (Abst.) Tysabri's effect on disease progression in SPMS
       By: agate Date: March 14, 2018, 10:28 am
       ---------------------------------------------------------
       From The Lancet Neurology (March 12, 2018).This study was funded
       by Biogen. It shows that Tysabri didn't change the EDSS score
       for persons with SPMS but did improve arm functioning somewhat,
       using the 9-hole peg test:
       [quote][font=source sans pro]No treatment effect was observed on
       the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the
       T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the
       primary outcome. However, natalizumab treatment reduced 9HPT
       [9-hole peg test] progression (OR 0·56, 95% CI 0·40–0·80;
       nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90
       (20%) natalizumab-treated patients had serious adverse events.
       In part 2, 291 natalizumab-continuing patients and 274
       natalizumab-naive patients received natalizumab (median
       follow-up 160 weeks [range 108–221]). Serious adverse events
       occurred in 39 (13%) patients continuing natalizumab and in 24
       (9%) patients initiating natalizumab. [/font]
       [/quote]
  HTML http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30069-3/fulltext
       *****************************************************